The United States Food and Drug Administration (FDA) has granted regulatory approval to Pfizer’s targeted oncology medication Tukysa (tucatinib) in…
Read More
KymaThera pulls in $80m to bring breast cancer drug to clinic – Pharmaceutical Technology
San Diego-based biopharmaceutical company KymaThera has successfully closed an $80 million Series B financing round to propel its lead oncology…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Groundbreaking collaborative research from the University of Michigan and the University of California San Diego has uncovered a critical biological…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Researchers at the University of Michigan and the University of California San Diego have uncovered a critical biological mechanism that…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
A collaborative study conducted by researchers at the University of Michigan and the University of California San Diego has identified…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Breast milk nutrient shapes immune development in mice
A significant new study from the University of Chicago (UChicago; IL, USA), published in the prestigious journal Science, has illuminated…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
This seminal research, conducted by a collaborative team from the University of Michigan and the University of California San Diego,…
Read More
FDA Grants Priority Review to Roche’s Giredestrant for Early-Stage Breast Cancer, Signaling Potential Paradigm Shift in Adjuvant Therapy
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
Read More
